Segui
Giovanni Stelitano
Giovanni Stelitano
Affiliazione sconosciuta
Email verificata su universitadipavia.it
Titolo
Citata da
Citata da
Anno
Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents
LR Chiarelli, M Mori, D Barlocco, G Beretta, A Gelain, E Pini, M Porcino, ...
European journal of medicinal chemistry 155, 754-763, 2018
662018
New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents
LR Chiarelli, M Mori, G Beretta, A Gelain, E Pini, JC Sammartino, ...
Journal of Enzyme Inhibition and Medicinal Chemistry 34 (1), 823-828, 2019
332019
Multitargeting compounds: a promising strategy to overcome multi-drug resistant tuberculosis
G Stelitano, JC Sammartino, LR Chiarelli
Molecules 25 (5), 1239, 2020
302020
Shedding X-ray Light on the Role of Magnesium in the Activity of Mycobacterium tuberculosis Salicylate Synthase (MbtI) for Drug Design
M Mori, G Stelitano, A Gelain, E Pini, LR Chiarelli, JC Sammartino, G Poli, ...
Journal of Medicinal Chemistry 63 (13), 7066-7080, 2020
252020
Synthesis, characterization, and biological evaluation of new derivatives targeting MbtI as antitubercular agents
M Mori, G Stelitano, LR Chiarelli, G Cazzaniga, A Gelain, D Barlocco, ...
Pharmaceuticals 14 (2), 155, 2021
242021
Towards real-time and affordable strain-level metagenomics-based foodborne outbreak investigations using Oxford nanopore sequencing technologies
FE Buytaers, A Saltykova, S Denayer, B Verhaegen, K Vanneste, ...
Frontiers in Microbiology 12, 738284, 2021
212021
Structural and activity relationships of 6-sulfonyl-8-nitrobenzothiazinones as antitubercular agents
D Fan, B Wang, G Stelitano, K Savková, R Shi, S Huszár, Q Han, ...
Journal of Medicinal Chemistry 64 (19), 14526-14539, 2021
182021
Synthesis and assessment of the in vitro and ex vivo activity of salicylate synthase (Mbti) inhibitors as new candidates for the treatment of mycobacterial infections
M Mori, G Stelitano, A Griego, LR Chiarelli, G Cazzaniga, A Gelain, E Pini, ...
Pharmaceuticals 15 (8), 992, 2022
152022
Virtual screening and crystallographic studies reveal an unexpected γ-lactone derivative active against MptpB as a potential antitubercular agent
G Cazzaniga, M Mori, F Meneghetti, LR Chiarelli, G Stelitano, I Caligiuri, ...
European Journal of Medicinal Chemistry 234, 114235, 2022
122022
Mycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options
D Recchia, G Stelitano, A Stamilla, DL Gutierrez, G Degiacomi, ...
International Journal of Molecular Sciences 24 (5), 4635, 2023
112023
The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme
JM Ezquerra-Aznárez, G Degiacomi, H Gašparovič, G Stelitano, ...
International Journal of Molecular Sciences 23 (2), 771, 2022
112022
Iron acquisition and metabolism as a promising target for antimicrobials (bottlenecks and opportunities): where do we stand?
G Stelitano, M Cocorullo, M Mori, S Villa, F Meneghetti, LR Chiarelli
International Journal of Molecular Sciences 24 (7), 6181, 2023
92023
Development of 6-methanesulfonyl-8-nitrobenzothiazinone based antitubercular agents
R Shi, B Wang, G Stelitano, X Wu, Y Shan, Y Wu, X Wang, LR Chiarelli, ...
ACS Medicinal Chemistry Letters 13 (4), 593-598, 2022
92022
Targeting siderophore-mediated iron uptake in M. abscessus: a new strategy to limit the virulence of non-tuberculous mycobacteria
M Mori, G Stelitano, G Cazzaniga, A Gelain, A Tresoldi, M Cocorullo, ...
Pharmaceutics 15 (2), 502, 2023
62023
Functional investigation of the antitubercular drug target Decaprenylphosphoryl-β-D-ribofuranose-2-epimerase DprE1/DprE2 complex
JC Sammartino, M Morici, G Stelitano, G Degiacomi, G Riccardi, ...
Biochemical and Biophysical Research Communications 607, 49-53, 2022
62022
Improving protection to prevent bacterial infections: preliminary applications of reverse vaccinology against the main cystic fibrosis pathogens
M Cocorullo, LR Chiarelli, G Stelitano
Vaccines 11 (7), 1221, 2023
22023
Side Chain-Modified Benzothiazinone Derivatives with Anti-Mycobacterial Activity
D Fan, B Wang, G Stelitano, K Savková, O Riabova, R Shi, X Wu, ...
Biomedicines 11 (7), 1975, 2023
12023
The veterinary anti-parasitic selamectin is a novel inhibitor of the mycobacterial DprE1 enzyme
JM Ezquerra-Aznárez, G Degiacomi, H Gašparovič, G Stelitano, ...
bioRxiv, 2021.12. 04.471217, 2021
12021
Structural basis for specific inhibition of salicylate synthase from Mycobacterium abscessus
M Mori, M Cocorullo, A Tresoldi, G Cazzaniga, A Gelain, G Stelitano, ...
European Journal of Medicinal Chemistry 265, 116073, 2024
2024
Benzothiozinone derivatives with anti-tubercular Activity− Further side chain investigation
X Wu, W Wang, G Stelitano, O Riabova, B Wang, W Niu, M Cocorullo, ...
European Journal of Medicinal Chemistry 264, 115976, 2024
2024
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20